ArticleCureus2025
Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives Tofacitinib, an effective Janus kinase inhibitor (JAKi), has gained increasing interest in recent years for the management of refractory alopecia areata (AA). One of the most prevalent autoimmune diseases is AA, a kind of non-scarring alopecia. Therefore, the purpose of this study was to evaluate the efficacy of oral tofacitinib in treating AA, alopecia totalis (AT), and alopecia universalis (AU). Methodology This interventional study was conducted at Hamdard Medical University, Taj Medical Complex, using a non-probability consecutive sampling technique. The duration of the study was about six months. This study included 50 patients of both genders diagnosed with AA, AT, and AU, aged five years to 50 years, and who were fit for treatment with oral tofacitinib. Pediatric patients received 5 mg once daily, while adults received 5 mg twice daily. Treatment response was assessed at eight, 12, and 24 weeks using changes in the Severity of Alopecia Tool (SALT) score from baseline. A Chi-square test was used to compare SALT scores and percentage changes over the follow-up period. Results The study findings showed that the mean age of the patients was 25.6 ± 11.8 years. Of them, 23 (46.0%) were males, and 27 (54.0%) were females. The majority of the patients (39, 78.0%) had AA, with nine (18.0%) patients having AU, and two (4.0%) having AT. The mean (SD) pretreatment scalp hair loss was 62.48 ± 23.58 %, and the mean scalp involvement at 24-week follow-up was 10.5 ± 24.0%. The mean regrowth rate was 88.9 ± 24.5 %. Moreover, a statistically significant difference was observed between the changes in SALT score from baseline and the scores of SALT at eight, 12, and 24 weeks (p < 0.001). Conclusion This study concluded that administration of oral tofacitinib to AA patients had significantly improved hair growth. Additionally, it has been revealed to be a potentially efficacious therapy for the management of severe and refractory disease. However, our follow-up period was small, and some side effects, such as changes in lipid count and cardiovascular side effects, may take a longer time to develop; therefore, longer follow-up studies are needed to better evaluate the long-term safety of this drug in AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.